A phase I study of the safety and tolerability of four doses of cetuximab (C225) in patients with advanced solid tumors
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Mar 2010 Biomarkers information updated
- 31 Oct 2007 Status change from recruiting to completed.
- 07 May 2007 New trial record.